Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ghana Med J ; 56(4): 340-344, 2022 Dec.
Article in English | MEDLINE | ID: mdl-37575627

ABSTRACT

The co-existence of pheochromocytoma and pregnancy is rare, with poor maternal and foetal outcomes. This is a case report of a young Ghanaian woman with a pre-existing diagnosis of recurrent pheochromocytoma who became pregnant and experienced elevated blood pressure in the third trimester with proteinuria and abnormal liver function. She was managed as an in-patient and delivered a live baby via caesarean section at 34 weeks after detecting intra-uterine growth restriction. Management of such cases by a multidisciplinary team is recommended for optimal outcomes.


Subject(s)
Adrenal Gland Neoplasms , Pheochromocytoma , Pregnancy , Humans , Female , Pheochromocytoma/complications , Pheochromocytoma/diagnosis , Pheochromocytoma/surgery , Cesarean Section , Ghana , Neoplasm Recurrence, Local , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/surgery
2.
Ghana Med J ; 54(4): 207-214, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33883768

ABSTRACT

OBJECTIVES: Dexamethasone has beneficial effects on postoperative nausea and vomiting, however, many clinicians have raised legitimate concerns regarding its effect on blood glucose concentrations. This study determined the safety and efficacy of a single pre-operative dose of dexamethasone for PONV prophylaxis in patients undergoing breast surgery. DESIGN: Prospective, double-blind, placebo-controlled trial. SETTING: Surgical wards of the Korle-Bu Teaching Hospital, Accra, Ghana. PARTICIPANTS: The study was conducted among breast surgery patients. They were consecutively recruited and randomized into two groups: dexamethasone (n = 47) and placebo (n = 47). INTERVENTIONS: Patients in the dexamethasone group received 8mg (2mls of 4mg/ml) dexamethasone while those in the placebo group received 2mls of saline intravenously. PONV impact scores and blood glucose levels were recorded at 4, 8 and 24 hours postoperatively. MAIN OUTCOME MEASURES: Incidence of PONV and blood glucose levels. RESULTS: The incidence of postoperative nausea (PON) was lower in the dexamethasone group compared with the placebo group (12.8% vs. 29.8%; p-value= 0.044). There was no significant difference in the incidence of postoperative vomiting (POV) and PONV between the two groups. Blood glucose levels were higher in the dexamethasone group throughout the study period and significant at 8 and 24 hours postoperatively (p < 0.05). There was no difference in the incidence of clinically significant hyperglycemia between the groups (p-value = 0.169). CONCLUSION: A preoperative intravenous dexamethasone 8mg, reduces PON but not POV or PONV in breast surgery without clinically significant postoperative hyperglycemia. FUNDING: Non declared.


Subject(s)
Antiemetics/therapeutic use , Breast Neoplasms/surgery , Dexamethasone/therapeutic use , Postoperative Nausea and Vomiting/epidemiology , Adult , Aged , Antiemetics/administration & dosage , Dexamethasone/administration & dosage , Double-Blind Method , Female , Ghana/epidemiology , Hospitals, Teaching , Humans , Incidence , Middle Aged , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...